Galectin-3 levels are elevated following nintedanib treatment.

Gali Epstein ShochetAlon PomerantzDavid ShitritBecky Bardenstein-WaldKjetil AskMark SurberNoa RabinowiczYair LevySydney BenchetritEvgeny EdelsteinTali Zitman-Gal

Published in: Therapeutic advances in chronic disease (2020)

Nintedanib elevates Gal-3 levels in both experimental models, along with patient samples. These findings highlight the possibility of using combined inhibition therapy for patients with IPF.

Keyphrases

idiopathic pulmonary fibrosis
interstitial lung disease
case report
systemic sclerosis
replacement therapy